Long lasting fusion peptide inhibitors for hiv infection

Abstract

The present invention is concerned with This invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

1 . A compound of Formulae I-VIII 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         2 . A pharmaceutical composition comprising a compound as claimed in  claim 1  in combination with a pharmaceutically acceptable carrier. 
     
     
         3 . A composition as claimed in  claim 2  for inhibiting the activity of HIV, RSV, HPV, MeV or SIV. 
     
     
         4 . A method for inhibiting the activity of HIV, RSV, HPV, MeV or SIV in a subject comprising administering to a subject an effective amount of a compound as claimed in  claim 1 , alone or in combination with a pharmaceutically acceptable carrier. 
     
     
         5 . A conjugate comprising a compound as claimed in  claim 1  covalently bonded to a blood component. 
     
     
         6 . A method for extending the in vivo half-life of a compounds as claimed in  claim 1 , the method comprising covalently bonding the compound to a blood component.